Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance

Stock Track11-05

Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced revenue guidance for 2025.

The biopharmaceutical company, known for its cortisol-modulating therapeutics, reported Q3 revenue of $207.6 million, falling short of analyst expectations of $218.52 million. Despite representing a 13.75% increase from the same period last year, the revenue miss raised concerns among investors. Adding to the disappointment, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million.

Corcept's Q3 net income also saw a significant decrease, dropping to $19.7 million from $47.2 million in the same quarter last year. Earnings per share (EPS) came in at $0.16, beating the consensus estimate of $0.14, but still marking a substantial 60.98% decrease from the $0.41 per share reported in the previous year. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149507846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149507846","market":"hk","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance","media":"Stock Track","content":"<p>Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced revenue guidance for 2025.</p>\n\n<p>The biopharmaceutical company, known for its cortisol-modulating therapeutics, reported Q3 revenue of $207.6 million, falling short of analyst expectations of $218.52 million. Despite representing a 13.75% increase from the same period last year, the revenue miss raised concerns among investors. Adding to the disappointment, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million.</p>\n\n<p>Corcept's Q3 net income also saw a significant decrease, dropping to $19.7 million from $47.2 million in the same quarter last year. Earnings per share (EPS) came in at $0.16, beating the consensus estimate of $0.14, but still marking a substantial 60.98% decrease from the $0.41 per share reported in the previous year. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 17:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced revenue guidance for 2025.</p>\n\n<p>The biopharmaceutical company, known for its cortisol-modulating therapeutics, reported Q3 revenue of $207.6 million, falling short of analyst expectations of $218.52 million. Despite representing a 13.75% increase from the same period last year, the revenue miss raised concerns among investors. Adding to the disappointment, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million.</p>\n\n<p>Corcept's Q3 net income also saw a significant decrease, dropping to $19.7 million from $47.2 million in the same quarter last year. Earnings per share (EPS) came in at $0.16, beating the consensus estimate of $0.14, but still marking a substantial 60.98% decrease from the $0.41 per share reported in the previous year. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1149507846","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149507846","pubTimestamp":1762334549,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"个股追踪|Corcept Therapeutics盘前暴跌9.83%因Q3营收未达预期下调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced revenue guidance for 2025.\nThe biopharmaceutical company, known for its cortisol-modulating therapeutics, reported Q3 revenue of $207.6 million, falling short of analyst expectations of $218.52 million. Despite representing a 13.75% increase from the same period last year, the revenue miss raised concerns among investors. Adding to the disappointment, Corcept revised its full-year 2025 revenue guidance downward to $800-850 million from the previous range of $850-900 million.\nCorcept's Q3 net income also saw a significant decrease, dropping to $19.7 million from $47.2 million in the same quarter last year. Earnings per share (EPS) came in at $0.16, beating the consensus estimate of $0.14, but still marking a substantial 60.98% decrease from the $0.41 per share reported in the previous year. CEO Joseph K. Belanoff attributed the revenue impact to capacity constraints at their previous specialty pharmacy vendor, noting that new pharmacies have been added to meet increasing demand for their hypercortisolism treatment, Korlym. As the market digests these mixed results, investors will be closely watching how Corcept plans to address the revenue shortfall and improve profitability in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149507846","isCrawlerRequest":true}